Yulseung Sung

Yulseung Sung

Auto-generated profile, based on publicly available information

Yulseung Sung

Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon, Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
YSYulseung Sung
Yulseung Sung
IYIna Yoon
Ina Yoon
JHJung Min Han
Jung Min Han
Sung-Hoon KimSung-Hoon Kim
Sung-Hoon Kim
Although key tumorigenic and tumor-suppressive factors have been unveiled over the last several decades, cancer remains the most life-threatening disease. Multiomic analyses of patient samples and an in-depth understanding of tumorigenic processes have rapidly revealed unexpected pathologic associations of new cellular factors previously overlooked in cancer biology. In this regard, the newly discovered activities of human aminoacyl-tRNA synthases (ARSs) deserve attention not only for their pathological significance in tumorigenesis but also regarding diagnostic and therapeutic implications. ARSs are not only essential enzymes covalently linking substrate amino acids to cognate tRNAs for protein synthesis but also function as regulators of cellular processes by sensing different cellular conditions. With their catalytic role in protein synthesis and their regulatory role in homeostasis, functional alterations or dysregulation of ARSs might be pathologically associated with tumorigenesis. This review focuses on the potential implications of ARS genes and proteins in different aspects of cancer based on various bioinformatic analyses and experimental data. We also review their diverse activities involving extracellular secretion, protein–protein interactions, and amino acid sensing, which are related to cancers. The newly discovered cancer-related activities of ARSs are expected to provide new opportunities for detecting, preventing and curing cancers.

1 June 2023 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
YSYulseung Sung
Yulseung Sung
YYYa Chun Yu
Ya Chun Yu
JHJung Min Han
Jung Min Han
The macronutrients glucose, lipids, and amino acids are the major components that maintain life. The ability of cells to sense and respond to fluctuations in these nutrients is a crucial feature for survival. Nutrient-sensing pathways are thus developed to govern cellular energy and metabolic homeostasis and regulate diverse biological processes. Accordingly, perturbations in these sensing pathways are associated with a wide variety of pathologies, especially metabolic diseases. Molecular sensors are the core within these sensing pathways and have a certain degree of specificity and affinity to sense the intracellular fluctuation of each nutrient either by directly binding to that nutrient or indirectly binding to its surrogate molecules. Once the changes in nutrient levels are detected, sensors trigger signaling cascades to fine-tune cellular processes for energy and metabolic homeostasis, for example, by controlling uptake, de novo synthesis or catabolism of that nutrient. In this review, we summarize the major discoveries on nutrient-sensing pathways and explain how those sensors associated with each pathway respond to intracellular nutrient availability and how these mechanisms control metabolic processes. Later, we further discuss the crosstalk between these sensing pathways for each nutrient, which are intertwined to regulate overall intracellular nutrient/metabolic homeostasis.

3 January 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SPSeung Joon Park
Seung Joon Park
HYHee Chan Yoo
Hee Chan Yoo
EAEunyong Ahn
Eunyong Ahn
ELEnzhi Luo
Enzhi Luo
YKYeabeen Kim
Yeabeen Kim
JHJung Min Han
Jung Min Han
Pancreatic ductal adenocarcinoma (PDAC) exhibits severe hypoxia, which is associated with chemoresistance and worse patient outcome. It has been reported that hypoxia induces metabolic reprogramming in cancer cells. However, it is not well known whether metabolic reprogramming contributes to hypoxia. Here, we established that increased glutamine catabolism is a fundamental mechanism inducing hypoxia, and thus chemoresistance, in PDAC cells. An extracellular matrix component–based in vitro three-dimensional cell printing model with patient-derived PDAC cells that recapitulate the hypoxic status in PDAC tumors showed that chemoresistant PDAC cells exhibit markedly enhanced glutamine catabolism compared with chemoresponsive PDAC cells. The augmented glutamine metabolic flux increased the oxygen consumption rate via mitochondrial oxidative phosphorylation (OXPHOS), promoting hypoxia and hypoxia-induced chemoresistance. Targeting glutaminolysis relieved hypoxia and improved chemotherapy efficacy in vitro and in vivo. This work suggests that targeting the glutaminolysis–OXPHOS–hypoxia axis is a novel therapeutic target for treating patients with chemoresistant PDAC. Significance: Increased glutaminolysis induces hypoxia via oxidative phosphorylation-mediated oxygen consumption and drives chemoresistance in pancreatic cancer, revealing a potential therapeutic strategy of combining glutaminolysis inhibition and chemotherapy to overcome resistance.

25 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
KKKibum Kim
Kibum Kim
HYHee Chan Yoo
Hee Chan Yoo
BKByung Gyu Kim
Byung Gyu Kim
SKSulhee Kim
Sulhee Kim
YSYulseung Sung
Yulseung Sung
JHJung Min Han
Jung Min Han
All living organisms have the ability to sense nutrient levels to coordinate cellular metabolism. Despite the importance of nutrient-sensing pathways that detect the levels of amino acids and glucose, how the availability of these two types of nutrients is integrated is unclear. Here, we show that glucose availability regulates the central nutrient effector mTORC1 through intracellular leucine sensor leucyl-tRNA synthetase 1 (LARS1). Glucose starvation results in O-GlcNAcylation of LARS1 on residue S1042. This modification inhibits the interaction of LARS1 with RagD GTPase and reduces the affinity of LARS1 for leucine by promoting phosphorylation of its leucine-binding site by the autophagy-activating kinase ULK1, decreasing mTORC1 activity. The lack of LARS1 O-GlcNAcylation constitutively activates mTORC1, supporting its ability to sense leucine, and deregulates protein synthesis and leucine catabolism under glucose starvation. This work demonstrates that LARS1 integrates leucine and glucose availability to regulate mTORC1 and the metabolic fate of leucine.

30 April 2026 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
YSYulseung Sung
Yulseung Sung
DKDae Kyoung Kim
Dae Kyoung Kim
JKJun Se Kim
Jun Se Kim
SKSeong-Jang Kim
Seong-Jang Kim
JKJae Ho Kim
Jae Ho Kim
JHJung Min Han
Jung Min Han
Metabolic rewiring, a defining hallmark of cancer, sustains cell proliferation and biosynthesis while coordinating adaptive interactions within the tumor microenvironment (TME). Recent advances reveal that metabolism in the TME-comprising stromal, immune and endothelial components forms a complex metabolic network in which intercellular competition, cooperation and plasticity profoundly influence tumor progression and therapeutic responses. Here we integrate emerging evidence on the organizational principles of amino acid and lipid metabolism within the TME, emphasizing how nutrient fluxes shape immune evasion, therapeutic resistance and metabolic symbiosis. We highlight key mechanisms through which cancer and nonmalignant cells engage in reciprocal nutrient manipulation, focusing on glutamine, arginine, tryptophan, branched-chain amino acids and lipids. The dual roles of these metabolites in immune regulation and tumor growth reveal the limitations of traditional single-pathway targeting and advocate for a network-centric therapeutic approach. We further discuss how metabolite-derived signaling and epigenetic regulation reinforce cell state transitions and immune suppression. Current and emerging therapeutic strategies, including multitarget combinations and immune–metabolic synergies, are evaluated alongside translational challenges. Finally, we underscore the need for spatial metabolomics, liquid biopsy platforms and artificial intelligence-driven modeling to map nutrient competition and cooperative exchange within the TME, offering new opportunities for precision metabolic interventions.

3 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
YSYulseung Sung
Yulseung Sung
YYYa Chun Yu
Ya Chun Yu
MLMirim Lee
Mirim Lee
SLSeonghun Lim
Seonghun Lim
YLYechan Lee
Yechan Lee
JHJung Min Han
Jung Min Han
The mitochondrial glutamine transporter SLC1A5_var plays a central role in the metabolic reprogramming of cancer cells by facilitating glutamine import into mitochondria for energy production and redox homeostasis. Despite its critical function, the development of effective and selective inhibitors targeting SLC1A5_var has remained a significant challenge. Here, we introduce iMQT_020, a selective allosteric inhibitor identified through structure-based screening. iMQT_020 disrupts the trimeric assembly of SLC1A5_var, causing metabolic crisis in cancer cells and selectively suppressing their growth. Mechanistically, iMQT_020 reduces glutamine anaplerosis and oxidative phosphorylation, resulting in a broad disruption of cancer metabolism. Additionally, iMQT_020 treatment epigenetically upregulates PD-L1 expression, enhancing the efficacy of combination therapies with anti-PD-L1 immune checkpoint inhibitors. These findings highlight the therapeutic potential of targeting SLC1A5_var as a critical metabolic vulnerability in cancer and demonstrate that targeting allosteric interprotomer interactions is a novel and promising therapeutic strategy for cancer treatment.